DETECTING ACUTE COGNITIVE CHANGES IN ALZHEIMERS PATIENTS

检测阿尔茨海默病患者的急性认知变化

• 批准号: 2053279
• 负责人: LAURA P. SANDS
• 金额: $ 10.23万
• 依托单位: INSTITUTE ON AGING
• 依托单位国家: 美国
• 财政年份: 1993
• 资助国家: 美国
• 起止时间: 1993-09-30 至 1998-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2053279
• 关键词: Alzheimer's disease; anticholinergic agent; brain disorder chemotherapy; cognition disorders; dementia; diphenylhydramine; drug adverse effect; human subject; interview; mental disorder diagnosis; neurotoxins; psychosis

Alzheimer's patients can experience excess disability from delirium or toxic or metabolic encephalopathies. Even though demented patients are at higher risk than intact patients for delirium and toxic or metabolic encephalopathies, the symptoms often go unrecognized. This is in part because diagnosis is confounded by the overlap in symptoms between irreversible dementia and reversible toxic or metabolic encephalopathies. One critical difference is in the clinical course; Alzheimer's disease is characterized by an insidious onset and a gradual decrement in function, while delirium and other encephalopathies can be associated with changes over shorter periods of time. What is needed to facilitate case identification is an objective method for monitoring the cognitive functioning of Alzheimer's patients. This proposal details a program of research consisting of three studies designed to investigate delirium and related disorders in Alzheimer's patients and to clarify diagnostic methods. Study I involves the application of a statistical technique to repeated assessments of cognitive functioning in Alzheimer's patients to define the normal limits of within-patient variability in cognitive performance in patients with uncomplicated Alzheimer's disease, and therefore to establish what constitutes significant changes in functioning. Study II and Study III are designed to detail the toxic effects of anticholinergic drugs commonly prescribed to Alzheimer's patients. These studies will serve to assess the validity and clinical applicability of the methods developed in Study I. The outcome of the proposed research will be the development of a clinically applicable method for monitoring AD patients that will aid in the prevention of excess disability.

阿尔茨海默病患者可能会因谵妄或 中毒性或代谢性脑病。 即使痴呆症患者处于 比完整患者发生谵妄和中毒或代谢的风险更高 脑病的症状常常被忽视。 这是部分 因为诊断因症状之间的重叠而混淆 不可逆的痴呆和可逆的中毒性或代谢性脑病。 一个关键的区别在于临床过程。阿尔茨海默病是 其特点是起病隐匿，功能逐渐减弱， 而谵妄和其他脑病可能与变化有关 在较短的时间内。 案件办理需要什么手续 识别是监测认知能力的客观方法 阿尔茨海默病患者的功能。该提案详细介绍了一项计划 研究由三项研究组成，旨在调查谵妄和 阿尔茨海默病患者的相关疾病并澄清诊断 方法。 研究 I 涉及统计技术的应用 反复评估阿尔茨海默病患者的认知功能 定义患者内部认知变异的正常限度 患有无并发症的阿尔茨海默病的患者的表现，以及 因此，要确定什么构成重大变化 发挥作用。 研究 II 和研究 III 旨在详细说明有毒物质 常用于治疗阿尔茨海默病的抗胆碱能药物的作用 患者。 这些研究将用于评估有效性和临床效果 研究 I 中开发的方法的适用性。 拟议的研究将是开发一种临床适用的 监测 AD 患者的方法有助于预防 过度残疾。